Robert M. Stoekenbroek and John J. P. Kastelein are at the Department of Vascular Medicine, Academic Medical Centre, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
Checking for direct PDF access through Ovid
The nocebo effect might be involved in a substantial proportion of patients experiencing muscle symptoms attributed to statin therapy. This observation underlines the importance of patient counselling and physician opposition to misinformation. Nonetheless, clinicians face a reality in which many patients do not tolerate adequate statin therapy despite rigorous efforts. Novel treatment strategies are, therefore, much needed.Refers to Gupta, A. et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial — Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its nonrandomised non-blind extension phase. Lancethttp://dx.doi.org/10.1016/S0140-6736(17)31075-9 (2017)